

GLAXOSMITHKLINE PLC

Form 6-K

February 21, 2017

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Sir Andrew Witty
  - b) Position/status Chief Executive Officer
  - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 

Ordinary shares of 25 pence each ('Ordinary Shares')

  - a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction
 

The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan – Deferred Bonus and Matching Awards.
- c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£0.0000	67,867 (Deferred)
£0.0000	22,621 (Matching)

- Aggregated information
- d) Aggregated volume Price
 

Aggregated volume	90,448
Price	£0.0000
  - e) Date of the transaction 2017-02-20
  - f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Sir Andrew Witty
  - b) Position/status Chief Executive Officer

- c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- Ordinary shares of 25 pence each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 20 February 2017 under the Company's Deferred Annual Bonus Plan – Deferred Bonus and Matching Awards.
- c) Price(s) and volume(s)
- | Price(s) | Volume(s)         |
|----------|-------------------|
| £16.3353 | 31,898 (Deferred) |
| £16.3353 | 10,633 (Matching) |

- Aggregated information
- d) Aggregated volume Price 42,531  
£16.3353
- e) Date of the transaction 2017-02-20
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Ms E Walmsley
- b) Position/status CEO Designate
- c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction	The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan – Deferred Bonus and Matching Awards.
c) Price(s) and volume(s)	Price(s) Volume(s) £0.0000 14,860 (Deferred) £0.0000 4,954 (Matching)
d) Aggregated information	
d) Aggregated volume Price	19,814 £0.0000
e) Date of the transaction	2017-02-21
f) Place of the transaction	n/a

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Ms E Walmsley
  - b) Position/status CEO Designate
  - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

  - a) Description of the financial instrument

- b) Nature of the transaction
 

The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 21 February 2017 under the Company's Deferred

	Annual Bonus Plan – Deferred Bonus and Matching Awards.
	Price(s) Volume(s)
c) Price(s) and volume(s)	£16.3500 6,986 (Deferred) £16.3500 2,330 (Matching)
	Aggregated information
d) Aggregated volume Price	9,316 £16.3500
e) Date of the transaction	2017-02-21
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')	
a) Name	Mr D S Redfern
b) Position/status	Chief Strategy Officer
c) Initial notification/ amendment	Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	Ordinary shares of 25 pence each ('Ordinary Shares')
a) Description of the financial instrument	ISIN: GB0009252882

b) Nature of the transaction	The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan – Deferred Bonus and Matching Awards.
	Price(s) Volume(s)
c) Price(s) and volume(s)	£0.0000 12,115 (Deferred) £0.0000 4,039 (Matching)
	Aggregated information
d) Aggregated volume Price	16,154 £0.0000
e) Date of the transaction	2017-02-20
f) Place of the transaction	n/a

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr D S Redfern
  - b) Position/status Chief Strategy Officer
  - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 

Ordinary shares of 25 pence each ('Ordinary Shares')

  - a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction
 

The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 20 February 2017 under the Company's Deferred Annual Bonus Plan – Deferred Bonus and Matching Awards.
- c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£16.3425	5,809 (Deferred)
£16.3450	1,937 (Matching)
- d) Aggregated information
 

Aggregated volume	7,746
Price	£16.3431
- e) Date of the transaction
 

2017-02-20
- f) Place of the transaction
 

London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Ms C Thomas
  - b) Position/status SVP, Human Resources
  - c) Initial notification/ amendment Initial Notification
- 2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- Ordinary shares of 25 pence each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan – Deferred Bonus and Matching Awards.
- c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£0.0000	7,517 (Deferred)
£0.0000	2,506 (Matching)

Aggregated information

- d) Aggregated volume Price 10,023  
£0.0000
- e) Date of the transaction 2017-02-20
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms C Thomas
- b) Position/status SVP, Human Resources
- c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 20 February 2017 under the Company's Deferred Annual Bonus Plan – Deferred Bonus and Matching Awards.
c) Price(s) and volume(s)	Price(s) Volume(s) £16.3700 3,604 (Deferred) £16.3550 1,202 (Matching)
d) Aggregated information	
d) Aggregated volume Price	4,806 £16.3662
e) Date of the transaction	2017-02-20
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr P C Thomson
  - b) Position/status SVP, Communications & Government Affairs
  - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 

Ordinary shares of 25 pence each ('Ordinary Shares')

  - a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan – Deferred Bonus and

Matching Awards.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£0.0000	4,528 (Deferred)
	£0.0000	1,509 (Matching)

Aggregated information

d) Aggregated volume Price	6,037
	£0.0000
e) Date of the transaction	2017-02-20
f) Place of the transaction	n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr P C Thomson
b) Position/status	SVP, Communications & Government Affairs
c) Initial notification/ amendment	Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument	ISIN: GB0009252882
--------------------------------------------	--------------------

b) Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 20 February 2017 under the Company's Deferred Annual Bonus Plan – Deferred Bonus and Matching Awards.
------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£16.3450	2,171 (Deferred)
	£16.3500	724 (Matching)

Aggregated information

d) Aggregated volume Price	2,895
	£16.3462



Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- e) Date of the transaction 2017-02-20
- f) Place of the transaction London Stock Exchange  
(XLON)